Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovac’s Healive® Vaccine Not Responsible for Infant’s Death

publication date: Dec 31, 2008

Sinovac Biotech (北京科兴生物制品有限公司) reported that Healive®, the company’s hepatitis A vaccine, has been cleared of any responsibility in the death of a two-year-old infant, who had been given the vaccine just two days before his death. According to discoveries made during an autopsy, the cause of death was myocarditis, an inflammation of the muscular part of the heart, which is usually caused by infection. Healive was not a factor in this problem. More details...

Stock Symbol: (NYSE Alternext US: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital